Adogwa Owoicho, Davison Mark A, Vuong Victoria D, Khalid Syed, Lilly Daniel T, Desai Shyam A, Moreno Jessica, Cheng Joseph, Bagley Carlos
Rush University Medical Center, Chicago, IL, USA.
University of Texas South Western Medical Center, Dallas, TX, USA.
Global Spine J. 2019 Sep;9(6):598-606. doi: 10.1177/2192568218814235. Epub 2018 Nov 27.
Retrospective cohort study.
The purpose of this study is to assess change in opioid use before and after lumbar decompression and fusion surgery for patients with symptomatic lumbar stenosis or spondylolisthesis.
A large insurance database was queried for patients with symptomatic lumbar stenosis or spondylolisthesis undergoing index lumbar decompression and fusion procedures between 2007 and 2016. This database consists of 20.9 million covered lives and includes private/commercially insured and Medicare Advantage beneficiaries. Opioid use 6 months preoperatively through 2 years postoperatively was assessed.
The study included 13 257 patients that underwent 1-, 2-, or 3-level posterior lumbar instrumented fusion. Overall, 57.8% of patients used opioids preoperatively. Throughout the 6-month preoperative period, 2 368 008 opioid pills were billed for (51.6 opioid pills/opioid user/month). When compared with preoperative opioid use, patients billed fewer opioid medications in the 2-year period postoperatively: 33.6 pills/patient/month (8 851 616 total pills). In a multivariate logistic regression analysis, obesity (odds ratio [OR] 1.10, 95% CI 1.004-1.212), preoperative narcotic use (OR 3.43, 95% CI 3.179-3.708), length of hospital stay (OR 1.02, 95% CI 1.010-1.021), and receiving treatment in the South (OR 1.18, 95% CI 1.074-1.287) or West (OR 1.26, 95% CI 1.095-1.452) were independently associated with prolonged postoperative (>1 year) opioid use. Additionally, males (OR 0.87, 95% CI 0.808-0.945) were less likely to use long-term opioid therapy.
This study demonstrates that reduction in opioid use was observed postoperatively in comparison with preoperative values in patients with symptomatic lumbar stenosis or spondylolisthesis that underwent lumbar decompression with fusion. Further prospective studies that are more methodologically stringent are needed to corroborate our findings.
回顾性队列研究。
本研究旨在评估有症状的腰椎管狭窄症或腰椎滑脱症患者在腰椎减压融合手术后阿片类药物使用情况的变化。
查询一个大型保险数据库,以获取2007年至2016年间接受初次腰椎减压融合手术的有症状的腰椎管狭窄症或腰椎滑脱症患者。该数据库包含2090万参保人员,包括私人/商业保险和医疗保险优势计划受益人。评估术前6个月至术后2年的阿片类药物使用情况。
该研究纳入了13257例行1、2或3节段后路腰椎器械融合术的患者。总体而言,57.8%的患者术前使用阿片类药物。在术前6个月期间,共开具了2368008片阿片类药物(每位阿片类药物使用者每月51.6片)。与术前阿片类药物使用情况相比,患者术后2年开具的阿片类药物较少:每位患者每月33.6片(共8851616片)。在多因素逻辑回归分析中,肥胖(比值比[OR]1.10,95%置信区间1.004 - 1.212)、术前使用麻醉剂(OR 3.43,95%置信区间3.179 - 3.708)、住院时间(OR 1.02,95%置信区间1.010 - 1.021)以及在南部(OR 1.18,95%置信区间1.074 - 1.287)或西部(OR 1.26,95%置信区间1.095 - 1.452)接受治疗与术后长期(>1年)使用阿片类药物独立相关。此外,男性(OR 0.87,95%置信区间0.808 - 0.945)使用长期阿片类药物治疗的可能性较小。
本研究表明,与接受腰椎减压融合术的有症状的腰椎管狭窄症或腰椎滑脱症患者术前相比,术后阿片类药物使用量有所减少。需要更严格方法学的进一步前瞻性研究来证实我们的发现。